iLIVER Pub Date : 2023-11-28 DOI: 10.1016/j.iliver.2023.11.002

Shanshan Zhao , Lan Zhang , Junzhe Zhao , Farah Tasnim , Hanry Yu

{"title":"Publication characteristics and visualized analysis of research about liver sinusoidal endothelial cells","authors":"Shanshan Zhao , Lan Zhang , Junzhe Zhao , Farah Tasnim , Hanry Yu","doi":"10.1016/j.iliver.2023.11.002","DOIUrl":"https://doi.org/10.1016/j.iliver.2023.11.002","url":null,"abstract":"<div><h3>Background and aims</h3><p>Through visual analysis of related literature, the main research direction and hot spots of liver sinusoidal endothelial cells (LSECs) in recent 24 years were explored.</p></div><div><h3>Methods</h3><p>This study used bibliometric analysis with CiteSpace, VOSviewer, Biblioshiny and online analytic tool <span>bibliometric.com</span><svg><path></path></svg> to provide a quantitative analysis, hot spot mining, and commentary of articles published in the field of LSECs research. The relevant literature in the Web of Science Core Collection (WOSCC) was searched from 2000 to 2023. The publications with topics or titles or keywords containing LSECs were included into this study. The countries, organizations, journals, authors, and keywords of the publications were summarized and analyzed.</p></div><div><h3>Results</h3><p>This study included 3,747 publications from 14,132 authors belonging to 389 institutions in 61 countries/regions and published in 150 journals, with 156,309 citations. The United States contributed most (1,150) to the publications. The most productive institution was the University of Sydney. <em>Hepatology</em> accounts for the most output (293, 7.8%), European authors had a widespread cooperation. The most productive author was Adam DH with 68 papers. Immunological function of LSECs is research hot spot.</p></div><div><h3>Conclusion</h3><p>This study highlights key trends based on a large dataset of the most influential publications about LSECs research over a 24-year period. It provides important clues and ideas for researchers focusing in this area and facilitates future liver disease mechanism, understanding, and treatment.</p></div>","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"3 1","pages":"Article 100075"},"PeriodicalIF":0.0,"publicationDate":"2023-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772947823000506/pdfft?md5=ecdacfaa6950185d24d1155ccad17e0a&pid=1-s2.0-S2772947823000506-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139693900","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Volatile organic compounds for the detection of hepatocellular carcinoma—A scoping review 用于检测肝细胞癌的挥发性有机化合物--范围综述

iLIVER Pub Date : 2023-10-08 DOI: 10.1016/j.iliver.2023.09.001

Sayed Metwaly , Alicja Psica , Opeyemi Sogaolu , Irfan Ahmed , Ashis Mukhopadhya , Mirela Delibegović , Mohamed Bekheit

{"title":"Volatile organic compounds for the detection of hepatocellular carcinoma—A scoping review","authors":"Sayed Metwaly , Alicja Psica , Opeyemi Sogaolu , Irfan Ahmed , Ashis Mukhopadhya , Mirela Delibegović , Mohamed Bekheit","doi":"10.1016/j.iliver.2023.09.001","DOIUrl":"10.1016/j.iliver.2023.09.001","url":null,"abstract":"<div><p>Hepatocellular carcinoma (HCC) is an increasingly common and the second leading cause of cancer mortality worldwide with a 5-year survival rate about 12%. Less than 20% of HCC patients are eligible to curative treatment owing to the late presentation. Clearly, there is a need for a readily accessible, early screening tool. This scoping review critically appraises and synthesizes the current published knowledge about the use of exhaled volatile organic compounds (VOCs) as a potential noninvasive means for HCC detection aiming to advance this nascent field. A systematic electronic search was conducted. The search strategy included all studies published until the 24th of March 2023 using a combination of relevant keywords. The search yielded 9 publications using the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines. Two of the studies described in vitro experiments, and seven clinical studies were conducted on small groups of patients. Overall, 42 headspace gases were analyzed in the in vitro studies. Combined, the clinical studies included 420 HCC patients and 630 controls. The studies reported potential role for a combination of VOCs in the diagnosis of HCC. However, there is lack of consensus. Although there appears to be promise in VOCs research associated with HCC, there is no single volatile biomarker in exhaled breath attributed to HCC and data from extracted studies indicates a lack of standardization. Large multicentre population studies are required to verify the existence of VOCs linked to HCC.</p></div>","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"3 1","pages":"Article 100070"},"PeriodicalIF":0.0,"publicationDate":"2023-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772947823000452/pdfft?md5=cd14d50b37f5452cfcfbeb72231a1ecc&pid=1-s2.0-S2772947823000452-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135607246","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

HCC case management-related challenges: Think outside the box! 与HCC病例管理相关的挑战:跳出框框思考!

iLIVER Pub Date : 2023-09-01 DOI: 10.1016/j.iliver.2023.08.001

Nourhan Badwei

引用次数: 0

Prednisolone therapy accelerates recovery of severe drug-induced liver injury: A prospective, randomized controlled study 强的松龙治疗加速严重药物性肝损伤的恢复:一项前瞻性、随机对照研究

iLIVER Pub Date : 2023-09-01 DOI: 10.1016/j.iliver.2023.06.001

Fang-Jiao Song , Hong-Ling Liu , Ying Sun , Tian-Jiao Xu , Dong-Ze Li , Hai-Bo Wang , Shao-Jie Xin , Yu-Dong Wang , Gregory Cheng , George Lau , Sa Lv , Shao-Li You , Bing Zhu

{"title":"Prednisolone therapy accelerates recovery of severe drug-induced liver injury: A prospective, randomized controlled study","authors":"Fang-Jiao Song , Hong-Ling Liu , Ying Sun , Tian-Jiao Xu , Dong-Ze Li , Hai-Bo Wang , Shao-Jie Xin , Yu-Dong Wang , Gregory Cheng , George Lau , Sa Lv , Shao-Li You , Bing Zhu","doi":"10.1016/j.iliver.2023.06.001","DOIUrl":"https://doi.org/10.1016/j.iliver.2023.06.001","url":null,"abstract":"<div><h3>Background and aims</h3><p>Drug-induced liver injury (DILI) is one of the most serious adverse drug reactions and its incidence has been increasing rapidly. Accumulating evidence suggests that immune activation and systemic inflammatory responses are very important in the progression of DILI. Corticosteroids are often used in DILI, but their clinical usefulness remains controversial. We therefore conducted a prospective, randomized controlled study to investigate whether corticosteroid therapy can accelerate recovery and reduce mortality in severe DILI (SDILI).</p></div><div><h3>Methods</h3><p>SDILI patients with total bilirubin ≥171 μmol/L who presented to the Fifth Medical Center of Chinese PLA General Hospital, Beijing from 2016 to 2019 were randomly allocated to prednisolone and control groups. The endpoints were resolution of SDILI, defined as a decrease in total bilirubin of at least 35 μmol/L to <171 μmol/L, and overall survival at 6 months. Patients in the prednisolone group received prednisolone 60 mg/day therapy for the first 7 days. Patients with a decrease in total bilirubin of more than 35 μmol/L on day 8 continued on tapering doses of prednisolone; otherwise, prednisolone was discontinued.</p></div><div><h3>Results</h3><p>On day 8, 50.75% (34/67) and 26.47% (18/68) of the participants in the prednisolone and control groups, respectively, achieved the primary endpoint (<em>p</em> = 0.002). However, there was no significant difference in overall survival at 6 months: 95.52% (64/67) vs. 91.18% (62/68) in the prednisolone and control groups, respectively (<em>p</em> = 0.3). All deaths in both groups occurred in patients who failed to achieve SDILI resolution on day 8.</p></div><div><h3>Conclusion</h3><p>Prednisolone therapy may accelerate the recovery of SDILI.</p></div>","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"2 3","pages":"Pages 156-162"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49735360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluating Tislelizumab, Lenvatinib, and FOLFOX4-HAIC as a Conversion Therapy for Unresectable Hepatocellular Carcinoma 评估Tislelizumab, Lenvatinib和FOLFOX4-HAIC作为不可切除肝细胞癌的转换疗法

iLIVER Pub Date : 2023-09-01 DOI: 10.1016/j.iliver.2023.08.003

Kai Tan , Xiaojun He , Haoran Yuan , Shoujie Zhao , Chenyu Gong , Yaoyao Zhao , Haiyan Nan , Li Zang , Zhonghua Luo , Xilin Du

{"title":"Evaluating Tislelizumab, Lenvatinib, and FOLFOX4-HAIC as a Conversion Therapy for Unresectable Hepatocellular Carcinoma","authors":"Kai Tan , Xiaojun He , Haoran Yuan , Shoujie Zhao , Chenyu Gong , Yaoyao Zhao , Haiyan Nan , Li Zang , Zhonghua Luo , Xilin Du","doi":"10.1016/j.iliver.2023.08.003","DOIUrl":"https://doi.org/10.1016/j.iliver.2023.08.003","url":null,"abstract":"<div><h3>Background and aims</h3><p>Conversion therapy downstages tumors and renders patients with unresectable hepatocellular carcinoma (HCC) eligible for radical resection. This study aimed to evaluate the efficacy and safety of tislelizumab plus lenvatinib and hepatic artery infusion chemotherapy with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4-HAIC) as a first-line conversion therapy.</p></div><div><h3>Methods</h3><p>Clinical data from HCC patients who were treated with the triple therapy between April 2021 and April 2022 were retrospectively analyzed. The primary outcome included objective response rate (ORR), disease control rate (DCR), conversion resection rate (CRR), and treatment-related adverse events (TRAEs).</p></div><div><h3>Results</h3><p>A total of 18 patients completed conversion therapy assessment, which ended on March 27, 2023. The patients had a median age of 55.5 (37–72) years, and 94.4% were male. According to mRECIST, tumor shrinkage was observed in all patients, with an ORR of 94.4% (17/18), a DCR of 94.4% (17/18), and a median time to response of 1.4 (0.7–3.0) months. Successful conversion was observed in 61.1% (11/18) of patients (mRECIST). The CRR and pathological complete response were 38.9% (7/18) and 57.1% (4/7), respectively. The median progression-free survival (PFS) was 17.8 months, while median overall survival was not reached. The 6- and 9-month PFS rates were 83.3% and 66.7%, respectively. The most common TRAE (16/18 patients, 88.9%) was an increase in aspartate aminotransferase levels.</p></div><div><h3>Conclusion</h3><p>Tislelizumab combined with lenvatinib and FOLFOX4-HAIC achieved a high conversion rate and acceptable toxicity in patients with unresectable HCC, suggesting that this combination may represent a new conversion strategy for this population.</p></div>","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"2 3","pages":"Pages 163-169"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49717277","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Radio-granular hydrogels for image-guided tumor brachytherapy 影像引导肿瘤近距离治疗用放射颗粒水凝胶

iLIVER Pub Date : 2023-09-01 DOI: 10.1016/j.iliver.2023.08.006

Shilong Shao , Xiao Xu , Gan Lin , Gang Liu

引用次数: 0

General-motors diet: A quick fix for steatotic live liver donors 通用马达饮食:脂肪肝活体供体的快速修复

iLIVER Pub Date : 2023-09-01 DOI: 10.1016/j.iliver.2023.08.002

Anish Gupta, Abhideep Chaudhary, Gaurav Sood, Niteen Kumar, Imtiakum Jamir, Aditya Shriya, Vipin Pal Singh, Rekha Subramaniyam, Hitesh Soni, Milind Mandwar

{"title":"General-motors diet: A quick fix for steatotic live liver donors","authors":"Anish Gupta, Abhideep Chaudhary, Gaurav Sood, Niteen Kumar, Imtiakum Jamir, Aditya Shriya, Vipin Pal Singh, Rekha Subramaniyam, Hitesh Soni, Milind Mandwar","doi":"10.1016/j.iliver.2023.08.002","DOIUrl":"https://doi.org/10.1016/j.iliver.2023.08.002","url":null,"abstract":"<div><h3>Background and aims</h3><p>GM (General-Motors) diet is a low-calorie 7-day diet plan using complex carbohydrates used for quick weight loss. Dietary optimisation is known to decrease steatosis and improve outcomes in liver donors. We evaluated the efficacy and feasibility of using GM diet in steatotic live liver donors (LLD).</p></div><div><h3>Methods</h3><p>LLDs who either had BMI > 30 kg/m<sup>2</sup>, Computerised tomography liver attenuation index (CT-LAI) < 0 HU, Magnetic resonance (MR) fat-fraction of >10% were started on GM diet for 1 week. Records of these LLDs and their recipients were retrieved retrospectively and analysed. Weight, liver function tests(LFT), MR fat-fraction, CT-LAI, hospital-stay and complications were analysed in LLDs while early graft dysfunction (EGD) and complications were assessed in recipients.</p></div><div><h3>Results</h3><p>A total of 51 LLDs with mean age of 34.6±9.5 years with baseline mean weight of 80.6±10.8 kg and BMI of 29.1±2.78 kg/m<sup>2</sup> were started on GM diet. After a week of following the GM diet, there was an average weight loss of 3.46±2.1 kg, a decrease in fat-fraction by 3.8%±2.7, and an improvement in CT-LAI by 6.7±3.7 HU. All patients could successfully undergo donor hepatectomy with an average postoperative ICU stay of 2.86±0.8 days and hospital stay of 6.82±0.81 days. No donor had steatosis > 10% on intraoperative Tru-cut biopsy and their post-operative outcomes were similar to normal liver donors. There were intra-abdominal collections in 2 donors requiring drainage and one required re-exploration for intestinal obstruction. There was EGD in 8 recipients (15.6%) and mortality in 1(1.9%) recipients.</p></div><div><h3>Conclusion</h3><p>GM diet is safe and effective regimen to reduce steatosis and increase healthy LLD pool without compromising donor or recipient safety.</p></div>","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"2 3","pages":"Pages 151-155"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49735246","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficiency and safety of sofosbuvir in Bangladeshi children with chronic hepatitis C virus infection 索非布韦治疗孟加拉国慢性丙型肝炎病毒感染儿童的有效性和安全性

iLIVER Pub Date : 2023-09-01 DOI: 10.1016/j.iliver.2023.06.002

Salahuddin Mahmud , Jahida Gulshan , Md. Belayet Hossain , Madhabi Baidya , Rafia Rashid , Farhana Tasneem , Ahmed Rashidul Hasan , Tanzila Farhana , Mohammed Reaz Mobarak , Md. Jahangir Alam , Syed Shafi Ahmed

{"title":"Efficiency and safety of sofosbuvir in Bangladeshi children with chronic hepatitis C virus infection","authors":"Salahuddin Mahmud , Jahida Gulshan , Md. Belayet Hossain , Madhabi Baidya , Rafia Rashid , Farhana Tasneem , Ahmed Rashidul Hasan , Tanzila Farhana , Mohammed Reaz Mobarak , Md. Jahangir Alam , Syed Shafi Ahmed","doi":"10.1016/j.iliver.2023.06.002","DOIUrl":"https://doi.org/10.1016/j.iliver.2023.06.002","url":null,"abstract":"<div><h3>Background and aims</h3><p>Currently, treatment with oral direct-acting antivirals is recommended for all hepatitis C virus (HCV)-infected pediatric patients. The aim of this study was to evaluate the efficacy and safety of sofosbuvir and ribavirin combination therapy for children and adolescents in Bangladesh who are living with chronic HCV infection.</p></div><div><h3>Methods</h3><p>An experimental study was performed from January 2021 to December 2022. HCV polymerase chain reaction (PCR)-positive thalassemic children, who were 6–18 years of age, were enrolled by consecutive nonprobability sampling. Clinical features were recorded, and investigations were performed. All patients were initially treated with sofosbuvir (200 mg for 6- to 11-year-olds and 400 mg for 12- to 18-year-olds) and ribavirin (10–15 mg/kg/day) and were assessed clinically on a four-weekly basis, along with liver-function testing. The total duration of therapy was 24 weeks. HCV PCR was done at the end of treatment and 12 weeks after the completion of treatment to see the sustained virological response.</p></div><div><h3>Results</h3><p>There were 26 cases in total, with a mean age of 9.26 ± 2.82 years; 14 were males (53.8%), and 12 females (46.2%). Twenty-five (96.15%) patients achieved a sustained virological response, and the end-of-treatment PCR was negative. One patient (3.85%) was a nonresponder even after 24 weeks of treatment. The medication was well received, with only four patients (15.3%) reporting headaches that were reported untreated.</p></div><div><h3>Conclusion</h3><p>The combination of sofosbuvir and ribavirin is effective in treating chronic HCV infection and is not accompanied by any major negative side effects.</p></div>","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"2 3","pages":"Pages 146-150"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49717062","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The evolution of available pharmacological treatments for variceal bleeding secondary to portal hypertension: A scope review 门静脉高压继发静脉曲张出血的现有药物治疗进展:范围回顾

iLIVER Pub Date : 2023-09-01 DOI: 10.1016/j.iliver.2023.08.005

Eduarda Raísa Coser , Raphael Bernardo Neto , Izabel Cristina Meister Martins Coelho , Norma Possa Marroni , Claudio Augusto Marroni , Camila Moraes Marques

{"title":"The evolution of available pharmacological treatments for variceal bleeding secondary to portal hypertension: A scope review","authors":"Eduarda Raísa Coser , Raphael Bernardo Neto , Izabel Cristina Meister Martins Coelho , Norma Possa Marroni , Claudio Augusto Marroni , Camila Moraes Marques","doi":"10.1016/j.iliver.2023.08.005","DOIUrl":"https://doi.org/10.1016/j.iliver.2023.08.005","url":null,"abstract":"<div><p>Variceal bleeding is one of the main complications of portal hypertension and it presents with 30 to 50% mortality in hospitalized patients. During the period between 1990 to 2017, more than 1.32 million deaths in the world were related to cirrhosis what makes necessary to map available treatments to variceal bleeding secondary to portal hypertension and to analyze the results of the described treatments. The method selected to this study is a scoping review based on the methodology proposed by the Joanna Briggs Institute (JBI) and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews Checklist (PRISMA-SCr) guidelines. The guiding question was defined as: \"What treatments are available for variceal bleeding secondary to portal hypertension?\". Based on these, 2870 articles were identified in the databases, 2446 were screened and 562 were selected for analysis by title and abstract. The texts analyzed in full totaled 110, of which 36 articles published between 2001 and 2020 were selected, with quantitative approaches, case reviews, literature reviews, meta-analyses, and guidelines. It is concluded that beta-blockers are the drugs of choice for primary prophylaxis of variceal bleeding. As for secondary prophylaxis, there is an association of these with nitrates and endoscopic ligation. With regard to acute bleeding, the use of vasoactive drugs is chosen, especially terlipressin. Finally, it is important to emphasize that there is a shortage of clinical studies and a need for investment in new therapies.</p></div>","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"2 3","pages":"Pages 170-176"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49717252","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

More precise measurement of irregular splenic volume in cirrhotic patients with portal hypertension 肝硬化合并门静脉高压症患者不规则脾体积的更精确测量

iLIVER Pub Date : 2023-06-01 DOI: 10.1016/j.iliver.2023.04.002

Xiao Chen , Tao Yang , Dong Wang , Bo Huang , Yanlong Cao , Jianguo Lu , Lei Cai , Jikai Yin

{"title":"More precise measurement of irregular splenic volume in cirrhotic patients with portal hypertension","authors":"Xiao Chen , Tao Yang , Dong Wang , Bo Huang , Yanlong Cao , Jianguo Lu , Lei Cai , Jikai Yin","doi":"10.1016/j.iliver.2023.04.002","DOIUrl":"https://doi.org/10.1016/j.iliver.2023.04.002","url":null,"abstract":"<div><h3>Background and aims</h3><p>Splenomegaly often occurs in cirrhotic patients with portal hypertension (PHT), and therefore, the efficacy and accuracy of conventional methods for measuring splenic volume are a matter of question in these patients. Here, we developed a novel approach to assess true splenic volume more precisely.</p></div><div><h3>Methods</h3><p>High-quality thin-slice computed tomography data of 112 cirrhotic patients with PHT were obtained and reviewed. Both the conventional measurement and a novel formula obtained from 3-dimensional reconstruction software were used to estimate splenic volume, and the accuracy was compared and verified.</p></div><div><h3>Results</h3><p>In PHT patients, the splenic volume calculated using the conventional method was significantly less than that calculated using the 3-dimensional software. We found that the splenic volume was significantly positively correlated with splenic indices of length (L), thickness (T), and width (W) and also the diameter of the splenic vein. Using these indices, we propose 2 novel formulas using the software to estimate the splenic volume more accurately: SV = 69.686 × L + 53.077 × W + 103.525 × T + 314.510 × diameter of splenic vein −2266.209 (<em>p</em> < 0.01, <em>R</em><sup><em>2</em></sup> = 0.805). And a more practical simplified formula: SV' = 0.504 × L × W × Τ + 319.762 × diameter of splenic vein −81.66 (<em>p</em> < 0.01, <em>R</em><sup><em>2</em></sup> = 0.784).</p></div><div><h3>Conclusion</h3><p>Although the conventional formula has been widely used for years, it is not suitable for an enlarged spleen. We developed 2 novel formulas for estimating splenic volume from clinical data that were more appropriate for cirrhotic patients with PHT.</p></div>","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"2 2","pages":"Pages 109-115"},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49735115","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

iLIVER最新文献